Dennis J. Slamon - Publications, H-index & Citations

Back

Dennis J. Slamon

ucla

126H-index

986Paper Count

10.0WCitation Count

Published Papers 207

Publication Date

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates

Scientific Reports

IF3.9

2026-05-07

OAAI

Simon Davenport; Bin Xie; Kevin Hamblett; Diana Hausman; Ivonne Villalobos; Hardeep P. Singh; David Cobrinik; David S. B. Hoon; Jian-Yuan Zhou; Maria Sibug-Saber; Yanling Ma; Gottfried E. Konecny; Martin Heur; Dennis J. Slamon; Michael F. Press

Save

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆

ESMO Open

IF8.3

2025-10-17

OAAI

J. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi

Save

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer

Targeted Oncology

IF4

2025-10-14

OAAI

Richard S. Finn; Hope S. Rugo; Javier Cortes; Sibylle Loibl; Grace Foley; Eric Gauthier; Yao Wang; Sindy Kim; Lars Anders; Dennis J. Slamon

Save

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

ONCOLOGIST

IF4.2

2025-09-01

OAAI

Blasco, Andrea; Lopez-Tarruella, Sara; Urruticoechea, Ander; Carrasco, Eva; Spera, Gonzalo; Martin, Miguel; Bermejo, Begona; Chap, Linnea; Ruiz-Borrego, Manuel; Crown, John; Garcia-Saenz, Jose A.; Chan, Arlene; Guerrero-Zotano, Angel; Semiglazov, Vladimir; Calvo, Lourdes; Pienkowski, Tadeusz; Herranz, Jesus; Slamon, Dennis

Save

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2025-09-01

OAAI

Lambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P.; Harbeck, Nadia; Swain, Sandra M.; Geyer, Charles E.; Slamon, Dennis J.; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A.; Krop, Ian E.; Winer, Eric P.; Anderson, Richard A.

Save

Phase II study of efficacy and safety of palbociclib in patients with recurrent ovarian cancer

International Journal of Gynecological Cancer

IF4.7

2025-07-28

OAAI

Gottfried E. Konecny; Tara M. Davidson; Coriolan L. Lebreton; Leah A. Marsh; Deandra K. Chetram; Hunter J. Atkinson; Melissa C. Larson; Ann L. Oberg; Nabilah Abdelaal; Jordyn Silverstein; Aminah Jatoi; Anita Washburn; Jill Burton; Sean Dowdy; Liying Zhang; Dorothy Hallberg; Victor E. Velculescu; Dennis J. Slamon; Andrea E. Wahner-Hendrickson

Save

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2025-04-10

OAAI

Garcia-Saenz, Jose A.; Spera, Gonzalo; Pollan, Marina; Bermejo, Begona; Ruiz-Borrego, Manuel; Chan, Arlene; Martin, Miguel; Guerrero-Zotano, Angel; Calvo, Lourdes; Rodriguez-Lescure, Alvaro; Marin, Maria; Chap, Linnea; Crown, John; Pienkowski, Tadeusz; Bee, Valerie; Casas, Maribel; Polonio, Oscar; Bezares, Susana; Slamon, Dennis

Save

Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2L early breast cancer (EBC)

ANNALS OF ONCOLOGY

IF65.4

2024-12-01

PREAI

Xu, B.; Stroyakovskiy, D.; Sohn, J.; Park, Y. H.; Huang, C-S.; Lu, Y-S.; Jung, K. H.; Chan, A.; Zhang, J.; Lee, J.; Kim, J. H.; Chung, C-F.; Slamon, D.; Sakalosh, V.; Gao, M.; Amin, K.; Islam, S.; Im, S-A.

Save

Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Konecny, G. E.; Hendrickson, A. E. Wahner; Winterhoff, B.; Adjei, A. A.; Kung, A.; Miller, L-L.; Press, M. F.; Qazi, I.; Scholler, N.; Dokainish, H.; Letrent, S.; Slamon, D.

Save

Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies

NPJ BREAST CANCER

IF7.6

2024-06-29

OAAI

Cheang, Maggie Chon U.; Rimawi, Mothaffar; Johnston, Stephen; Jacobs, Samuel A.; Bliss, Judith; Pogue-Geile, Katherine; Kilburn, Lucy; Zhu, Zhou; Schuster, Eugene F.; Xiao, Hui; Swaim, Lisa; Deng, Shibing; Lu, Dongrui R.; Gauthier, Eric; Tursi, Jennifer; Slamon, Dennis J.; Rugo, Hope S.; Finn, Richard S.; Liu, Yuan

Save

High-throughput screening identifies potential combinatorial therapies to overcome lenvatinib resistance in liver cancer

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Chau, Kevin; McDermott, Martina S.; Gong, KeWei; Slamon, Dennis J.

Save

ALPPL2 is involved in MAPK signal pathway of pancreatic cancer

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Gong, Ke Wei; Hamid, Bilal; Castro, Kenny W.; McDermott, Martina S.; Epstein, Forrest; Chau, Kevin; Hu, Chuhong; Zhang, Jun; Lu, Ming; Hoffstrom, Benjamin G.; O'Brien, Neil A.; Slamon, Dennis J.

Save

TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

O'Brien, Neil A.; McDermott, Martina S. J.; Zhang, Jun; Lu, Ming; Gong, Ke Wei; Hoffstrom, Benjamin; Jia, Wei Ping; Luo, Tong; Madrid, Athena M.; Liang, Min; Glaspy, John A.; Slamon, Dennis J.

Save

Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1)

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

McDermott, Martina S.; O'Brien, Neil A.; Lu, Ming; Zhang, Jun; Gong, KeWei; Hoffstrom, Benjamin; Luo, Tong; Liang, Min; Jia, Weiping; Chau, Kevin; Presta, Leonard; Glaspy, John; Slamon, Dennis J.

Save

Ribociclib plus Endocrine Therapy in Early Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-03-21

PREAI

Slamon, Dennis; Lipatov, Oleg; Nowecki, Zbigniew; McAndrew, Nicholas; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A.; Huang, Chiun-Sheng; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Ruiz-Borrego, Manuel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Afenjar, Karen; Fresco, Rodrigo; Severin, Irene; Ji, Yan; Ghaznawi, Farhat; Li, Zheng; Zarate, Juan P.; Chakravartty, Arunava; Taran, Tetiana; Hortobagyi, Gabriel

Save

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy (vol 22, 175, 2023)

MOLECULAR CANCER

IF33.9

2023-10-30

OAAI

Mcdermott, Martina S. J.; Browne, Brigid C.; Conlon, Neil T.; O'Brien, Neil A.; Slamon, Dennis J.; Henry, Michael; Meleady, Paula; Clynes, Martin; Dowling, Paul; Crown, John; O'Donovan, Norma

Save

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-10-03

PREAI

O'Brien, Neil A.; McDermott, Martina S. J.; Zhang, Jun; Gong, Ke Wei; Lu, Ming; Hoffstrom, Benjamin; Luo, Tong; Ayala, Raul; Chau, Kevin; Liang, Min; Madrid, Athena M.; Donahue, Timothy R.; Glaspy, John A.; Presta, Leonard; Slamon, Dennis J.

Save

Invasive diseaseefree survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HRD/HER2-early breast cancer (EBC)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

PREAI

Bardia, A.; Hortobagyi, G. N.; Lipatov, O.; McAndrew, N. P.; Lacko, A.; Sohn, J.; Hart, L.; Crown, J. P.; Im, S-A.; Harbeck, N.; O'Shaughnessy, J.; Xu, B.; Barrios, C. H.; Moroose, R.; Gonzalez, V.; Fresco, R.; Ghaznawi, F.; Waters, S.; Chakravartty, A.; Slamon, D.

Save

First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Konecny, G. E.; Hendrickson, A. E. Wahner; Winterhoff, B.; Machado, A.; Chander, C.; Davenport, S.; Bilic, S.; Miller, L. L.; Chung, A.; Press, M. F.; Letrent, S.; Slamon, D.

Save

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Fasching, P. A.; Slamon, D.; Nowecki, Z.; Kukielka-Budny, B. D.; Stroyakovskiy, D.; Yardley, D.; Huang, C.; Chan, A.; Chia, S.; Martin, M.; Rugo, H. S.; Loi, S.; Hurvitz, S. A.; Untch, M.; Afenjar, K.; Fresco, R.; Danyliv, A.; Ferrusi, I.; Li, Z.; Hortobagyi, G. N.

Save

Research Directions